SCHEMBL21810255

SCHEMBL21810255

Cc1cc(F)cc(-c2cnc(Cl)c(C=O)c2N2CCC(NC(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 1/20 0.42
▸ SKP1 P63208 1/20 0.42
▸ SKP2 Q13309 1/20 0.42
▸ SSTR2 P30874 6/20 0.40
▸ SYK P43405 2/20 0.40
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ PARP1 P09874 2/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ BTK Q06187 1/20 0.38
▸ SUV39H2 Q9H5I1 3/20 0.37
▸ PARP2 Q9UGN5 1/20 0.37
▸ RET P07949 1/20 0.37
▸ SMO Q99835 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20500376 0.92 CKS1B (0.43) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL20500354 0.90 CKS1B (0.42) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL20500433 0.89 SSTR2 (0.42) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL20500366 0.89 CKS1B (0.42) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL20500364 0.89 CKS1B (0.41) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL21810209 0.89 CKS1B (0.41) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL20500372 0.86 CKS1B (0.40) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL30255293 0.84 CKS1B (0.42) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL20500356 0.84 CKS1B (0.42) CKS1BSKP1SKP2SSTR2SYK
SCHEMBL30078443 0.84 CNR1 (0.42) SSTR2CNR1CNR2ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4548974-A2 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2025-05-07 — — EP disclosed
EP-3853218-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2025-02-19 — — EP disclosed
US-11834462-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-12-05 — — US disclosed
US-20230022513-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-01-26 — — US disclosed
US-20220048924-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-02-17 — — US disclosed
US-11186590-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-11-30 — — US disclosed
EP-3853218-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-07-28 — — EP disclosed
US-20200283453-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-09-10 — — US disclosed
US-10696689-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-06-30 — — US disclosed
WO-2020061046-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2020-03-26 — — WO disclosed
US-20200087318-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022513-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885
US-20220048924-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885
US-20200087318-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885
US-11834462-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885
US-20200283453-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885
US-11186590-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885
US-10696689-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback